Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®.

ABSTRACT:

Background

Inconsistent responses to anticancer immunotherapies demonstrate the need for non-invasive methods to detect treatment responses earlier than conventional medical imaging methods allow. The chimeric monoclonal antibody, APOMAB®, targets dead tumour cells following DNA-damaging anticancer treatments via binding of the ribonuclear protein, La/SSB, an intracellular protein overexpressed by tumour cells. La/SSB only becomes accessible to APOMAB binding in post-apoptotic necrotic tumour cells.

Methods

We assessed the ability of APOMAB to detect dead tumour cells after immune-mediated cell death. Co-culture of GD2-specific chimeric antigen receptor (CAR) T-cells with GD2-expressing cancer cell lines demonstrated specific and dose-dependent binding of APOMAB to the resul

SUBMITTER: Liapis V 

PROVIDER: S-EPMC12164067 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature